Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 3Rectal Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 29Paclitaxel 22Taxes 16Bevacizumab 15Specimen Handling 10Immunoglobulin G 10Disulfides 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Biopsy 9veliparib 8olaparib 8liposomal doxorubicin 7cediranib 6Doxorubicin 6Docetaxel 6Topotecan 5Chemotherapy, Adjuvant 4Oxaliplatin 3Immunohistochemistry 3Gene Expression Profiling 3temsirolimus 2reolysin 2oregovomab 2ipatasertib 2cabozantinib 2berzosertib 2belinostat 2atezolizumab 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Fallopian Tube Neoplasms × Panitumumab × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡